Great write up on PTX. Interesting that Ph2 breast cancer continues to do well - 40% complete response and 60% partial and only one more patient required to have a complete response to expand the Ph2 trial - but no real insights yet to AML. Other interesting point that
“Ptx 200 we might partner, but with PTX-1 00, we could realistically carry that ourselves because we have a fast-track development plan,” he said.
http://ptxtherapeutics.com/wp-content/uploads/2018/08/180829_PTX_MED_BioWorld-Media-Release.pdf
Ann: June 2018 Appendix 4C - Quarterly, page-47
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
